Table 2.

Molecular results investigated on 20 samples with Next Generation Sequency Technology. Legend: n.v. = not valuable; AF = Allele Frequency.

ID Patient	Cells/ Section	% Tumoral Cells	Mutational Analysis		RNA Fusion
			Cytomatrix	Surgical Tissue	Cytomatrix	Surgical Tissue
1	3000	90%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 17.65%	AF: 43%
2	1200	90%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 35.91%	AF: 36%
3	1200	100%	Wildtype	Wildtype	Negative	Negative
4	2000	90%	Wildtype	Wildtype	Negative	Negative
5	600	70%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 20.95%	AF: 33.6%
6	1500	70%	Wildtype	Wildtype	CUX1-RET.	CUX1-RET.
					C10R12	C10R12
7	1000	90%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 24.89%	AF: 10.84%
8	250	80%	n.v.	Wildtype	n.v.	n.v.
9	700	90%	Wildtype	Wildtype	Negative	Negative
10	1000	70%	Wildtype	Wildtype	Negative	Negative
11	2200	80%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 38.11%	AF: 36.33%
12	1800	80%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 36.11%	AF: 18.66%
13	600	50%	Wildtype	Wildtype	Negative	Negative
14	700	80%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 41.68%	AF: 33.5%
15	2500	70%	BRAF	BRAF	-	-
			pVal600E/c.1799 T > A	pVal600E/c.1799 T > A
			AF: 20.99%	AF: 11.26%
16	500	80%	n.v.	n.v.	n.v.	n.v.
17	1200	90%	Wildtype	Wildtype	Negative	Negative
18	1700	90%	HRAS	HRAS	-	-
			p.Gln61arg/c.182	p.Gln61arg/c.182
			A > G	A > G
			AF: 47.05%	AF: 46.11%
19	3000	80%	Wildtype	Wildtype	Negative	Negative
20	600	80%	Wildtype	Wildtype	Negative	Negative